CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Visual-Acoustic Biofeedback Treatment +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04858022
NCT04858022Phase 2Completed

Online Assessment and Enhancement of Auditory Perception for Speech Sound Errors: Visual Acoustic Biofeedback for RSE Via Telepractice

Montclair State University·interventional·Posted Apr 23, 2021·Updated Feb 17, 2026

In Brief

A Phase 2 clinical trial evaluating Visual-Acoustic Biofeedback Treatment and No Treatment for Speech Sound Disorder. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This research will meet a public health need by evaluating the efficacy of speech intervention supplemented with real-time visual-acoustic biofeedback when delivered using remote technologies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 23, 2021
Enrollment StartJan 15, 2022
Primary CompletionApr 15, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.2 years ago

Interventions

Visual-Acoustic Biofeedback Treatmentbehavioral

In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.

No Treatmentother

10-week period of no treatment